Please ensure Javascript is enabled for purposes of website accessibility

Is AstraZeneca Stock a Buy?

By Keith Speights – Aug 14, 2020 at 6:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker's current lineup, pipeline, and dividend make the question an easy one to answer.

AstraZeneca (AZN 0.06%) ranks as one of the top big drugmakers in terms of stock performance so far this year. That's not surprising, considering the company's solid quarterly updates and the positive publicity that it's garnered for its coronavirus vaccine program.

But is AstraZeneca stock a buy now? My answer is a resounding "yes." Here are three key reasons why.

People holding two large jigsaw puzzle pieces, one with a light bulb drawn on it and the other with an equal sign and dollar sign drawn on it

Image source: Getty Images.

1. Multiple juggernaut franchises

Some drugmakers specialize in one area where they really make their mark. AstraZeneca's success stems from not just one, but multiple juggernaut franchises. 

Sales for AstraZeneca's oncology drugs continue to soar. Lung cancer drug Tagrisso now generates close to 16% of the company's total revenue. Imfinzi and Lynparza are picking up strong momentum, as is Calquence. Overall, AstraZeneca's oncology drugs delivered year-over-year sales growth of 26% in the first half of 2020.

AstraZeneca is also a major player in cardiovascular, renal, and metabolism (CVRM) indications. Sales for diabetes drug Farxiga and blood thinner Brilinta are growing by double-digit percentages. The strength of these two blockbuster drugs is more than enough to offset sales declines for diabetes drugs Bydureon, Byetta, and Onglyza.

The company's respiratory and immunology franchise continues to deliver solid growth, as well. Respiratory drugs Symbicort and Fasenra are leading the way, with sales jumping 23% and 44%, respectively, in the first half of the year.

2. A loaded pipeline

Wall Street analysts project that AstraZeneca will grow its earnings by an average annual rate of 19% over the next five years. The company's current lineup will fuel much of this growth. But AstraZeneca also boasts a pipeline loaded with potential winners.

The company has 166 programs in its pipeline. Close to two dozen of them are in phase 3 clinical studies. Many of these late-stage programs target additional indications for already-approved drugs, including Imfinzi and Lynparza. AstraZeneca also has new late-stage drug candidates, notably including roxadustat, which targets the treatment of anemia in chronic kidney disease, and tezepelumab in treating asthma.

There's one pipeline candidate that's understandably generating a lot of interest right now: investigational COVID-19 vaccine AZD1222. AstraZeneca teamed up with the University of Oxford earlier this year to develop the vaccine candidate. AZD1222 is now one of only a handful of COVID-19 vaccine candidates in late-stage testing. The company has lined up several high-dollar supply agreements, including a $1.2 billion deal with the U.S. government to supply up to 300 million doses.

3. Don't forget the dividend

Megablockbuster franchises in oncology, CVRM, and respiratory and immunology combined with a deep and promising pipeline make this big pharma stock a good pick. But don't forget AstraZeneca's dividend yield of more than 2.5%.

How important is that dividend? Over the last 10 years, the total return of the stock has more than doubled its share-price appreciation thanks to the power of reinvested dividends.

Any reasons for concern?

All stocks face risks. AstraZeneca isn't an exception. There's always a possibility that a pipeline candidate could flop in clinical testing. Current drugs could face increased competition. Some might also worry that AstraZeneca won't make much money from AZD1222 since the company has committed to supplying the coronavirus vaccine for no profit in Europe.

However, my view is that AstraZeneca's opportunities far outweigh its risks. It's also important to note that the company could make a profit from AZD1222 once the COVID-19 pandemic is over. For investors looking for a relatively low-risk growth opportunity that offers an attractive dividend, AstraZeneca looks like a great pick.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.21 (0.06%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.